#1 Clinical Trials Search in Europe

Exemestane

Exemestane is a medication being studied in various clinical trials for its potential in treating different types of cancer, particularly breast cancer. This article summarizes key information from several clinical trials investigating the use of exemestane alone or in combination with other drugs. These studies aim to evaluate its effectiveness, safety, and potential benefits for patients with different stages and types of cancer.

Table of Contents

What is Exemestane?

Exemestane is a medication primarily used in the treatment of breast cancer. It is known by its brand name Aromasin[1]. Exemestane belongs to a class of drugs called aromatase inhibitors, which play a crucial role in hormone therapy for certain types of breast cancer[2].

How Exemestane Works

Exemestane works by blocking the production of estrogen in the body. Estrogen can stimulate the growth of certain breast cancer cells. By reducing the amount of estrogen, exemestane helps to slow down or stop the growth of these cancer cells[3].

The medication specifically targets an enzyme called aromatase, which is responsible for converting other hormones into estrogen. By inhibiting this enzyme, exemestane effectively lowers the overall estrogen levels in the body[4].

Conditions Treated with Exemestane

Exemestane is primarily used to treat the following conditions:

  • Breast Cancer: Specifically, it is used in postmenopausal women with estrogen receptor-positive (ER+) breast cancer. This means the cancer cells grow in response to estrogen[2].
  • Advanced Breast Cancer: It can be used in cases where the cancer has spread to other parts of the body (metastatic breast cancer)[5].
  • Early-Stage Breast Cancer: Exemestane may be used as adjuvant therapy, which means it’s given after the main treatment (such as surgery) to help prevent the cancer from returning[6].

In some cases, exemestane has also been studied for use in other conditions:

  • Endometrial Cancer: Some research has explored its potential in treating advanced or recurrent endometrial cancer[7].
  • Prostate Cancer: There have been studies investigating its use in advanced prostate cancer[8].

Dosage and Administration

Exemestane is typically taken as a tablet by mouth. The standard dose is usually:

  • 25 mg once daily[4]
  • It is often recommended to take the medication after a meal[2]

The duration of treatment can vary depending on the specific condition and treatment plan. In some cases, it may be taken for several years[6].

Potential Side Effects

Like all medications, exemestane can cause side effects. Some of the potential side effects include:

  • Hot flashes
  • Fatigue
  • Joint pain or stiffness
  • Headache
  • Sweating
  • Nausea

More serious side effects can include an increased risk of osteoporosis (bone thinning) and fractures. Your doctor will monitor you for these effects and may recommend calcium and vitamin D supplements[5].

Ongoing Clinical Trials

Exemestane continues to be studied in various clinical trials to explore its effectiveness in different scenarios and combinations. Some ongoing areas of research include:

  • Combining exemestane with other medications to enhance its effectiveness[2]
  • Using exemestane as part of neoadjuvant therapy (treatment given before the main treatment) in breast cancer[9]
  • Investigating genetic factors that may influence how patients respond to exemestane[1]

Combination Therapies

Researchers are exploring the use of exemestane in combination with other medications to potentially improve treatment outcomes. Some combinations being studied include:

  • Exemestane + Enzalutamide: This combination is being studied for advanced breast cancer[2]
  • Exemestane + Everolimus: This combination has shown promise in treating certain types of advanced breast cancer
  • Exemestane + Bicalutamide: This combination has been studied in prostate cancer[8]

It’s important to note that these combination therapies are still being researched and may not be standard treatment options. Always consult with your healthcare provider about the most appropriate treatment plan for your specific situation.

Aspect Details
Main Cancer Types Breast cancer (advanced, early-stage), endometrial cancer, prostate cancer
Common Dosage 25 mg oral tablet, once daily
Combination Therapies PI3K/mTOR inhibitors, CDK4/6 inhibitors, bicalutamide, celecoxib
Primary Outcomes Progression-free survival, clinical benefit rate, objective response rate
Secondary Outcomes Overall survival, duration of response, quality of life, pharmacokinetics
Treatment Settings Neoadjuvant, adjuvant, advanced/metastatic disease
Patient Populations Postmenopausal women, hormone receptor-positive breast cancer, various cancer stages
Safety Assessments Adverse events, toxicity profiles, musculoskeletal effects

FAQ

  • What is exemestane and how does it work? Exemestane is an aromatase inhibitor that works by reducing the production of estrogen in the body. It is used to treat hormone receptor-positive breast cancer in postmenopausal women by blocking the growth-stimulating effects of estrogen on cancer cells.
  • In which types of cancer is exemestane being studied? Exemestane is primarily being studied in breast cancer clinical trials, including advanced and early-stage breast cancer. Some trials are also exploring its potential in other cancers such as endometrial cancer and prostate cancer.
  • How is exemestane typically administered in clinical trials? In most clinical trials, exemestane is administered orally as a tablet, usually at a dose of 25 mg once daily. The duration of treatment varies depending on the specific trial design and objectives.
  • What are some common combinations being studied with exemestane? Clinical trials are investigating exemestane in combination with various other drugs, including PI3K/mTOR inhibitors, CDK4/6 inhibitors, and other targeted therapies. Some studies are also comparing exemestane alone to combination treatments.
  • What are the main outcomes being measured in exemestane clinical trials? Common outcomes measured in exemestane clinical trials include progression-free survival, overall survival, objective response rate, clinical benefit rate, duration of response, and quality of life. Safety and tolerability are also important aspects being evaluated in these studies.

Ongoing Clinical Trials on Exemestane

  • Study on Everolimus and Exemestane for Patients with Metastatic Breast Cancer

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Hungary

  • Study on Chemotherapy and Aromatase Inhibitors (Exemestane, Letrozole, Anastrozole) for Post-Menopausal Patients with Early Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study of PF-07220060 and Fulvestrant for Adults with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer After Previous Treatment

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Belgium Bulgaria Czechia Denmark Finland France +8

  • Study on Abemaciclib and Endocrine Therapy for Patients with Advanced Hormone Receptor Positive HER2 Negative Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study of Paclitaxel, Carboplatin and Letrozole Treatment Compared to Letrozole Alone in Patients with Stage II-IV Low-Grade Serous Ovarian or Peritoneal Cancer

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Ireland

  • Study on Palbociclib and Drug Combination for Patients with Hormone Receptor Positive, HER2-Positive Metastatic Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Portugal Spain

  • Evaluation of Abemaciclib with Standard Endocrine Therapy in Patients with High Risk, Early Stage, Hormone Receptor Positive, HER2 Negative Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +10

  • Study of Palbociclib as an Alternative to Chemotherapy for Older Patients with High-Risk Early Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Belgium France Germany Italy Poland Portugal +1

  • Study of tucatinib, pertuzumab and trastuzumab combination for patients with HER2-positive metastatic breast cancer who have brain metastases after local therapy

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of Imlunestrant, Fulvestrant, Exemestane, and Abemaciclib for Patients with Advanced Estrogen Receptor Positive, HER2 Negative Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium France Germany Greece Italy +2

Glossary

  • Aromatase inhibitor: A type of drug that reduces estrogen production in the body by blocking the enzyme aromatase, which is responsible for converting androgens into estrogens.
  • Hormone receptor-positive: Refers to cancer cells that have receptors for either estrogen or progesterone, making them potentially responsive to hormone therapy.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall survival (OS): The length of time from either the date of diagnosis or the start of treatment that patients are still alive.
  • Objective response rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Clinical benefit rate (CBR): The percentage of patients with advanced or metastatic cancer who have achieved complete response, partial response, or stable disease for a minimum period of time.
  • Neoadjuvant therapy: Treatment given before the main treatment, usually to shrink a tumor before surgery.
  • Adjuvant therapy: Additional treatment given after the primary treatment to lower the risk of cancer recurrence.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and excreted by the body.
  • Pharmacodynamics (PD): The study of the biochemical and physiological effects of drugs on the body and the mechanisms of drug action.

References

  1. https://clinicaltrials.gov/study/NCT01655004
  2. https://clinicaltrials.gov/study/NCT02007512
  3. https://clinicaltrials.gov/study/NCT00002777
  4. https://clinicaltrials.gov/study/NCT01658176
  5. https://clinicaltrials.gov/study/NCT00793546
  6. https://clinicaltrials.gov/study/NCT00810706
  7. https://clinicaltrials.gov/study/NCT01965080
  8. https://clinicaltrials.gov/study/NCT00031889
  9. https://clinicaltrials.gov/study/NCT01648608